Whistleblower Sarah Behnke's lawsuit leads to a $290 million judgment against CVS Caremark for overcharging Medicare on ...

CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive ...

CVS Caremark must now shoulder nearly $290 million in damages and penalties after being found complicit in a Medicare Part D ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Notably, the case came from a whistleblower lawsuit filed by Sarah Behnke, a former Medicare Part D actuary at Aetna, who ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company’s healthcare benefits arm are beginning to show ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

A Pennsylvania judge has ordered CVS to pay $289 million in damages as part of a long-running whistleblower case. | A ...

UnitedHealthcare just confirmed it is under investigation by the Department of Justice for Medicare Advantage fraud. It’s not ...